Sumatriptan News and Research

RSS
Safeguard Scientifics reports consolidated net income of $121.8M for second quarter 2011

Safeguard Scientifics reports consolidated net income of $121.8M for second quarter 2011

POZEN reports revenue of $4.5 million for first quarter 2011

POZEN reports revenue of $4.5 million for first quarter 2011

U.S. District Court grants preliminary injunction to POZEN's Treximet patent lawsuit

U.S. District Court grants preliminary injunction to POZEN's Treximet patent lawsuit

Aradigm fourth quarter revenue is $144,000 for 2010

Aradigm fourth quarter revenue is $144,000 for 2010

Cilag, POZEN enter license agreement to develop and commercialize MT 400

Cilag, POZEN enter license agreement to develop and commercialize MT 400

POZEN files motion for Treximet patent litigation against Par

POZEN files motion for Treximet patent litigation against Par

Zogenix completes enrollment in ZX002 Phase 3 study in opioid-experienced adults with moderate to severe pain

Zogenix completes enrollment in ZX002 Phase 3 study in opioid-experienced adults with moderate to severe pain

Zogenix receives 2011 DDP Industry Achievement Award for SUMAVEL DosePro

Zogenix receives 2011 DDP Industry Achievement Award for SUMAVEL DosePro

Zogenix, Desitin receive MAA approval for SUMAVEL DosePro in Germany and the UK

Zogenix, Desitin receive MAA approval for SUMAVEL DosePro in Germany and the UK

Zogenix announces underwriters partial exercise of over-allotment option in initial public offering

Zogenix announces underwriters partial exercise of over-allotment option in initial public offering

Zogenix's SUMAVEL DosePro Needle-free Delivery System wins 2010 Most Innovative Product award

Zogenix's SUMAVEL DosePro Needle-free Delivery System wins 2010 Most Innovative Product award

Zogenix, Desitin receive MAA approval for SUMAVEL DosePro needle-free delivery system in Denmark

Zogenix, Desitin receive MAA approval for SUMAVEL DosePro needle-free delivery system in Denmark

Denmark grants marketing authorization for SUMAVEL DosePro Needle-Free Delivery System

Denmark grants marketing authorization for SUMAVEL DosePro Needle-Free Delivery System

Zogenix completes enrollment in ZX002 Phase 3 study for moderate to severe pain

Zogenix completes enrollment in ZX002 Phase 3 study for moderate to severe pain

Safeguard Scientifics third quarter aggregate revenue of partner companies increases 73% to $109.6 million

Safeguard Scientifics third quarter aggregate revenue of partner companies increases 73% to $109.6 million

OptiNose presents sumatriptan Phase II trial results at 2nd European Headache and Migraine Trust International

OptiNose presents sumatriptan Phase II trial results at 2nd European Headache and Migraine Trust International

POZEN reports net loss of $8.6M for third quarter 2010 vs. net income of $6.7M for third quarter 2009

POZEN reports net loss of $8.6M for third quarter 2010 vs. net income of $6.7M for third quarter 2009

Par Pharmaceutical second-quarter total net revenues decrease 37% to $255.5 million

Par Pharmaceutical second-quarter total net revenues decrease 37% to $255.5 million

POZEN reports $16.2M net income for second-quarter 2010

POZEN reports $16.2M net income for second-quarter 2010

Safeguard Scientifics second-quarter aggregate revenue of partner companies increase 47% to $91.6 million

Safeguard Scientifics second-quarter aggregate revenue of partner companies increase 47% to $91.6 million